Hanlim Pharm
CompanySouth KoreaFounded 1974
Hanlim Pharm develops 2 assets, the furthest in phase 3 (Crecheck in hypertension). Mostly small molecule acting on lipid and ceramide metabolism, HMGCR and PPARA; based in South Korea, founded in 1974.
- 2
- Assets
- Furthest stage
- Phase 3
- 8
- Trials
- 0
- Signals
Pipeline
2HMG-CoA reductase inhibitor that lowers low-density lipoprotein cholesterol
Phase 3, Small molecule, Lipid and ceramide metabolism, HMGCR, hypertension, primary hypercholesterolemia
Peroxisome proliferator-activated receptor alpha agonist that regulates lipid metabolism.
Phase 3, Small molecule, Lipid and ceramide metabolism, PPARA, complex dyslipidemia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Trials8
- Similar companies6